Reclaimed at end of life
Tonnes as filed. Totals combine re-used, recycled and safely disposed, because filers place comparable activity in different columns.
reporting_boundary_changed. Reporting boundary changed across years: FY 2021-22 Standalone basis, FY 2022-23 Standalone basis, FY 2023-24 Standalone basis, FY 2024-25 Standalone. Year-on-year figures cover different entities.
| Category | FY 2022-23 | FY 2024-25 |
|---|---|---|
| Plastics including packaging | not filed | 4,251 |
| E-waste | not filed | 0 |
| Hazardous waste | not filed | 0 |
| Other waste | not filed | 0 |
| Total reclaimed | 0 | 4,251 |
Recycled or reused input material
Share of total material by value, per material line as the company named it. Each line carries its own denominator, so they are never summed or averaged.
| Input material, as filed | FY 2022-23 | FY 2024-25 |
|---|---|---|
| As 100% of the Company’s production activities focus on manufacturing pharmaceutical products, there is no utilisation of re-used or recycled input material. There is no scope for reusing or recycling any input material due to the criticality involved in producing and safely delivering pharmaceutical products from the perspective of consumer health, safety, compliance with pertinent regulations, and clinical studies. | 0.0% | not filed |
| As 100% of the Company's production activities focus on manufacturing pharmaceutical products, there is no utilisation of re-used or recycled input material. There is no scope for reusing or recycling any input material due to the criticality involved in producing and safely delivering pharmaceutical products from the perspective of consumer health, safety, compliance with pertinent regulations, and clinical studies. | not filed | 0.0% |
NIC codes filed
Products and services accounting for 90 percent of turnover, latest filing.
| Code | Description as filed | Share of turnover |
|---|---|---|
| 210 | Manufacture of pharmaceuticals, medicinal and chemical products | 100.00% |
Source filings
| Year | Basis | Taxonomy | Turnover as filed |
|---|---|---|---|
| FY 2022-23 | Standalone basis | 2021-09-30 | 2,03,94,63,00,000 |
| FY 2024-25 | Standalone | 2025-05-31 | 2,30,03,33,00,000 |
Figures read from BRSR XBRL as filed. Nothing estimated or restated. How this works · Report an error